Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition
- Conditions
- Interventions
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 17
- Registration Number
- NCT03275597
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2024-07-12
- Target Recruit Count
- 9
- Registration Number
- NCT03237377
- Locations
- 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin
- Conditions
- Interventions
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 6
- Registration Number
- NCT03234153
- Locations
- 🇨🇭
Departement of Medical Oncology, University Hospital Berne, Berne, Switzerland
A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 54
- Registration Number
- NCT03212469
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT03204812
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT03206073
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 61
- Registration Number
- NCT03164772
- Locations
- 🇺🇸
Research Facility, Milwaukee, Wisconsin, United States
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1186
- Registration Number
- NCT03164616
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03158064
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Terence Friedlander, MD
- Registration Number
- NCT03150836
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.